Leerink Partnrs Issues Negative Forecast for MNMD Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Leerink Partnrs dropped their Q4 2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a research report issued to clients and investors on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($0.54) for the quarter, down from their previous estimate of ($0.53). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($2.05) EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26).

Several other equities research analysts have also commented on MNMD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a research note on Wednesday, October 8th. Canaccord Genuity Group raised their price objective on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, August 1st. Lifesci Capital raised Mind Medicine (MindMed) to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Needham & Company LLC set a $28.00 target price on Mind Medicine (MindMed) and gave the company a “buy” rating in a research report on Monday, October 13th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $26.50.

Mind Medicine (MindMed) Stock Down 2.7%

Shares of NASDAQ:MNMD opened at $12.14 on Wednesday. The firm has a 50 day simple moving average of $11.46 and a 200-day simple moving average of $9.23. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $14.43. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $923.73 million, a PE ratio of -5.95 and a beta of 2.57.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Mind Medicine (MindMed) by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. BIT Capital GmbH acquired a new position in Mind Medicine (MindMed) in the 3rd quarter valued at $26,000. CWM LLC raised its position in Mind Medicine (MindMed) by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after buying an additional 1,796 shares during the last quarter. Fifth Third Bancorp raised its position in Mind Medicine (MindMed) by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after buying an additional 3,300 shares during the last quarter. Finally, Sound Income Strategies LLC acquired a new stake in shares of Mind Medicine (MindMed) in the 3rd quarter worth $46,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Insider Transactions at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, insider Mark Sullivan sold 11,278 shares of the company’s stock in a transaction that occurred on Thursday, September 25th. The stock was sold at an average price of $9.77, for a total transaction of $110,186.06. Following the completion of the sale, the insider directly owned 293,852 shares of the company’s stock, valued at $2,870,934.04. This represents a 3.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Karlin sold 7,704 shares of the stock in a transaction that occurred on Thursday, September 25th. The stock was sold at an average price of $9.77, for a total value of $75,268.08. Following the sale, the insider directly owned 430,625 shares of the company’s stock, valued at $4,207,206.25. The trade was a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 44,779 shares of company stock worth $437,491. Company insiders own 2.45% of the company’s stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.